Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial

• Published in: Current Alzheimer research Vol. 14; no. 4; p. 403
• Main Authors: Decourt, Boris, Drumm-Gurnee, Denise, Wilson, Jeffrey, Jacobson, Sandra, Belden, Christine, Sirrel, Sherye, Ahmadi, Michael, Shill, Holly, Powell, Jessica, Walker, Aaron, Gonzales, Amanda, Macias, Mimi, Sabbagh, Marwan N
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2017
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - drug therapy; Alzheimer Disease - psychology; Cognition - drug effects; Double-Blind Method; Educational Status; Female; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; Patient Dropouts; Thalidomide - adverse effects; Thalidomide - therapeutic use; Treatment Failure; clinical trial; Adverse events; thalidomide; Alzheimer's Disease; tolerability; cognitive tests

To date there is no cure for Alzheimer's disease (AD). After amyloid beta immunotherapies have failed to meet primary endpoints of slowing cognitive decline in AD subjects, the inhibition of the beta-secretase BACE1 appears as a promising therapeutic approach. Pre-clinical data obtained in APP2...